NCT07129187View on ClinicalTrials.gov

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2030

Conditions

Early Breast CancerHER2 + Breast CancerStage II Breast CancerStage III Breast Cancer

Interventions

DRUG

SHR-A1811

Drug: SHR-A1811 4.8mg/kg

All Listed Sponsors

lead

Chuan Wang

OTHER